Drug Trial Radar · NCT00028743
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Last checked: Nov 19, 2026Latest source record: Apr 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
819
Actual
Start
Aug 31, 2001
Primary completion
Mar 5, 2008
Study completion Jan 10, 2013
Sponsor
- Lead sponsor
- NCIC Clinical Trials GroupResearch network
- Sponsor type
- Research network
- Collaborators
- European Organisation for Research and Treatment of Cancer - EORTC; Grupo Español de Investigación en Cáncer de Ovario
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating ovarian epithelial, primary peritoneal, or fallopian tube cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different combination chemotherapy regimens in treating patients who have stage IIB, stage III, or stage IV ovarian epithelial cancer , primary peritoneal cancer, or fallopian tube cancer.
Conditions
- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer
Interventions
carboplatinDrug
Arm 1 = 4 cycles vs Arm 2 = 8 cycles AUC5 (30 mins) day 1 of 21 day cycle
cisplatinDrug
4 cycles 50mg/m2 (60 mins) day 1 of 21 day cycle
paclitaxelDrug
Arm 1 = 4 cycles vs Arm 2 = 8 cycles 175mg/m2 (3 hours) day 1 of 21 day cycle
topotecan hydrochlorideDrug
4 cycles .75mg/m2 (30 mins) days 1-5 of 21 day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survivalTime frame: Mar 2008
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
BCCA - Cancer Centre for the Southern Interior
Kelowna, British Columbia, Canada
Lions Gate Hospital
North Vancouver, British Columbia, Canada
BCCA - Fraser Valley Cancer Centre
Surrey, British Columbia, Canada
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada
CancerCare Manitoba
Winnipeg, Manitoba, Canada
The Moncton Hospital
Moncton, New Brunswick, Canada
Atlantic Health Sciences Corporation
Saint John, New Brunswick, Canada
Dr. H. Bliss Murphy Cancer Centre
St. John's, Newfoundland and Labrador, Canada
QEII Health Sciences Center
Halifax, Nova Scotia, Canada
Northeast Cancer Center Health Sciences
Greater Sudbury, Ontario, Canada
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
Cancer Centre of Southeastern Ontario at Kingston
Kingston, Ontario, Canada
Grand River Regional Cancer Centre
Kitchener, Ontario, Canada
London Regional Cancer Program
London, Ontario, Canada
Ottawa Health Research Institute - General Division
Ottawa, Ontario, Canada
Niagara Health System
St. Catharines, Ontario, Canada
Thunder Bay Regional Health Science Centre
Thunder Bay, Ontario, Canada
Univ. Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
Windsor Regional Cancer Centre
Windsor, Ontario, Canada
PEI Cancer Treatment Centre,Queen Elizabeth Hospital
Charlottetown, Prince Edward Island, Canada
CHUM - Hopital Notre-Dame
Montreal, Quebec, Canada
Hopital du Sacre-Coeur de Montreal
Montreal, Quebec, Canada
CHUQ-Pavillon Hotel-Dieu de Quebec
Québec, Quebec, Canada
Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.